Industry
Pfizer licenses three in vivo CAR-T therapies from Starna
Pfizer gains rights outside Greater China to three early-stage CAR-T therapies being developed for autoimmune diseases.

Pfizer has licensed rights to three preclinical in vivo CAR-T programs from Starna Therapeutics, a China-based company. The therapies are being developed for autoimmune diseases. Pfizer will pay $330 million upfront and could pay up to $2.3 billion more in development and commercial milestones, plus royalties on sales of approved products.
Starna’s approach uses RNA to reprogram cells inside the body. Pfizer will lead clinical development outside Greater China and said it plans to manufacture the products for clinical trials at its U.S. facilities. The specific targets and indications have not been disclosed.


